The Europe Insomnia Market would witness market growth of 3.3% CAGR during the forecast period (2022-2028).
Insomnia is becoming more prevalent across the globe. The industry is likely to advance as a result of rising stress levels, an aging population, and increased knowledge of the available treatment options for this disease. The introduction of medical devices and the development of new technologies are also being supported by the governments. Only a small number of medical devices, including the Fisher Stimulator, Alpha-Stim AID, and EBB Insomnia Therapy, have recently received approval. Nevertheless, they are anticipated to have a greater penetration due to favorable reimbursement policies as well as the development of handset combination therapy for treating insomnia.
The demand for sleep disorder treatment options is anticipated to be driven by rising raising the attention of the target condition as well as increased uptake of novel drugs and technology. Positive results from the use of devices & medications together are anticipated to support insomnia therapeutics over the course of the forecast period. The prevalence of insomnia is rising due to a number of other factors, including side effects from prescription and over-the-counter medications, arthritis, and excessive media consumption before bed. Additionally, the rise in psychiatric disorders and rising noise levels in urban areas are further leading to increasing cases of insomnia.
In contrast to 3% and 68% of those who did not experience sleep issues, it was discovered that 22% of severe insomniacs thought their quality of life was terrible and 28% thought it was good. But only 55% of people with severe insomnia ever have spoken with a doctor about it, and even fewer had done so in the previous 12 months. In Germany, insomnia is a common & ongoing problem, even when it is severe. Even though sleep issues significantly impact patients' quality of life and utilization of healthcare, it is also a condition that is underdiagnosed and for which people are reluctant to seek treatment for unidentified reasons. The insomnia market is expanding in this region as a result of the rising number of insomniac cases.
The Germany market dominated the Europe Insomnia Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $385.3 million by 2028. The UK market is registering a CAGR of 2.4% during (2022 - 2028). Additionally, The France would generate a CAGR of 4% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Hospital, Retail, and Others. Based on Therapy Type, the market is segmented into Pharmacological and Non-Pharmacological. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Insomnia Market will Hit $5.7 Billion by 2028, at a CAGR of 3.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
By Therapy Type
- Pharmacological
- Non-Pharmacological
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Eisai Co., Ltd.
- Merck Group
- Pfizer, Inc.
- Vanda Pharmaceuticals, Inc.
- Cadila Healthcare Ltd. (Zydus Cadila)
- Sanofi S.A.
- Viatris, Inc.
- Takeda Pharmaceutical Company Limited
- Purdue Pharma L.P.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Insomnia Market, by Distribution Channel
1.4.2 Europe Insomnia Market, by Therapy Type
1.4.3 Europe Insomnia Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Insomnia Market
Chapter 4. Europe Insomnia Market by Distribution Channel
4.1 Europe Hospital Market by Country
4.2 Europe Retail Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Insomnia Market by Therapy Type
5.1 Europe Pharmacological Market by Country
5.2 Europe Non-Pharmacological Market by Country
Chapter 6. Europe Insomnia Market by Country
6.1 Germany Insomnia Market
6.1.1 Germany Insomnia Market by Distribution Channel
6.1.2 Germany Insomnia Market by Therapy Type
6.2 UK Insomnia Market
6.2.1 UK Insomnia Market by Distribution Channel
6.2.2 UK Insomnia Market by Therapy Type
6.3 France Insomnia Market
6.3.1 France Insomnia Market by Distribution Channel
6.3.2 France Insomnia Market by Therapy Type
6.4 Russia Insomnia Market
6.4.1 Russia Insomnia Market by Distribution Channel
6.4.2 Russia Insomnia Market by Therapy Type
6.5 Spain Insomnia Market
6.5.1 Spain Insomnia Market by Distribution Channel
6.5.2 Spain Insomnia Market by Therapy Type
6.6 Italy Insomnia Market
6.6.1 Italy Insomnia Market by Distribution Channel
6.6.2 Italy Insomnia Market by Therapy Type
6.7 Rest of Europe Insomnia Market
6.7.1 Rest of Europe Insomnia Market by Distribution Channel
6.7.2 Rest of Europe Insomnia Market by Therapy Type
Chapter 7. Company Profiles
7.1 Eisai Co., Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Product Launches and Product Expansions:
7.1.5.2 Approvals and Trails:
7.2 Takeda Pharmaceutical Company Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Approvals and Trails:
7.3 Vanda Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.3.4 Recent strategies and developments:
7.3.4.1 Approval and Trails:
7.4 Cadila Healthcare Ltd. (Zydus Cadila)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Sanofi S.A.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Geographical Expansions:
7.6 Merck Group
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Acquisition and Mergers:
7.9.2.2 Geographical Expansions:
7.10. Purdue Pharma L.P.
7.10.1 Company Overview
TABLE 1 Europe Insomnia Market, 2018 - 2021, USD Million
TABLE 2 Europe Insomnia Market, 2022 - 2028, USD Million
TABLE 3 Europe Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 4 Europe Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 5 Europe Hospital Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Hospital Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Retail Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Retail Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 12 Europe Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 13 Europe Pharmacological Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Pharmacological Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Non-Pharmacological Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Non-Pharmacological Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Insomnia Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Insomnia Market by Country, 2022 - 2028, USD Million
TABLE 19 Germany Insomnia Market, 2018 - 2021, USD Million
TABLE 20 Germany Insomnia Market, 2022 - 2028, USD Million
TABLE 21 Germany Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 22 Germany Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 23 Germany Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 24 Germany Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 25 UK Insomnia Market, 2018 - 2021, USD Million
TABLE 26 UK Insomnia Market, 2022 - 2028, USD Million
TABLE 27 UK Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 28 UK Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 29 UK Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 30 UK Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 31 France Insomnia Market, 2018 - 2021, USD Million
TABLE 32 France Insomnia Market, 2022 - 2028, USD Million
TABLE 33 France Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 34 France Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 35 France Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 36 France Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 37 Russia Insomnia Market, 2018 - 2021, USD Million
TABLE 38 Russia Insomnia Market, 2022 - 2028, USD Million
TABLE 39 Russia Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 40 Russia Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 41 Russia Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 42 Russia Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 43 Spain Insomnia Market, 2018 - 2021, USD Million
TABLE 44 Spain Insomnia Market, 2022 - 2028, USD Million
TABLE 45 Spain Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 46 Spain Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 47 Spain Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 48 Spain Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 49 Italy Insomnia Market, 2018 - 2021, USD Million
TABLE 50 Italy Insomnia Market, 2022 - 2028, USD Million
TABLE 51 Italy Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 52 Italy Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 53 Italy Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 54 Italy Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 55 Rest of Europe Insomnia Market, 2018 - 2021, USD Million
TABLE 56 Rest of Europe Insomnia Market, 2022 - 2028, USD Million
TABLE 57 Rest of Europe Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 58 Rest of Europe Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 59 Rest of Europe Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 60 Rest of Europe Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 61 Key Information – Eisai Co., Ltd.
TABLE 62 Key Information – Takeda Pharmaceutical Company Limited
TABLE 63 Key Information – Vanda Pharmaceuticals, Inc.
TABLE 64 Key Information – Cadila Healthcare Ltd.
TABLE 65 Key Information – Sanofi S.A.
TABLE 66 key Information – Merck GrouP
TABLE 67 Key Information – Pfizer, Inc.
TABLE 68 key information – Viatris, Inc.
TABLE 69 Key Information – Currax Pharmaceuticals LLC
TABLE 70 Key Information – Purdue Pharma L.P.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Eisai Co., Ltd.
FIG 3 Recent strategies and developments: Currax Pharmaceuticals LLC